GSK (GSK) said Monday that it is partnering with the University of Oxford to investigate cancer prevention through vaccination, with GSK committing up to 50 million British pounds ($62.6 million) in funding over a minimum of three years.

The GSK-Oxford Cancer Immuno-Prevention program will focus on understanding precancer biology to uncover how cancer forms and identify potential vaccine strategies, the organizations said.

GSK's shares were up over 1% in recent Monday premarket activity.